Skip to main content

Kidney cancer

Kidney cancer

26-07-2022 | Oncology | News | Article

KEYNOTE-426 QoL data further support pembrolizumab–axitinib in RCC

Combination therapy with pembrolizumab plus axitinib results in similar health-related quality of life outcomes to that with sunitinib monotherapy for untreated advanced renal cell carcinoma, KEYNOTE-426 study data show.

22-07-2022 | Oncology | News | Article

L-arginine levels may predict ICI response

Baseline plasma L-arginine levels may predict response to immune checkpoint inhibitors in people with advanced cancers, say French researchers who found that low levels correlated with poorer outcomes.

21-07-2022 | Oncology | News | Article

Concomitant statins may improve advanced RCC nivolumab outcomes

Statins appear to be associated with improved outcomes among patients with metastatic renal cell carcinoma taking nivolumab, indicates a chart review.

Heart and stethoscope 2

14-07-2022 | Oncology | News | Article

ICIs associated with increased MACE risk

People with cancer receiving immune checkpoint inhibitors have a significantly higher risk for major adverse cardiovascular events than their unexposed counterparts or the general population, indicate real-world findings.

08-07-2022 | Oncology | News | Article

Immune-related toxicities signal improved ICI efficacy in people with cancer, autoimmune disease

US researchers have identified “a protective association” between immune-related toxic effects – either disease flares or immune-related adverse events – in people with autoimmune disease receiving immune checkpoint inhibitors for cancer.

07-07-2022 | Oncology | News | Article

Electronic health data picks up cancer gene–treatment interactions

Researchers have used computer-based analyses to identify and confirm a large number genetic biomarkers that predict cancer treatment outcomes, as well as gene–gene interactions that may modify the effects of targeted treatments.

01-07-2022 | Oncology | News | Article

FDA approval did not quash socioeconomic immunotherapy access disparities

US FDA immunotherapy approval led to a significant increase in use, but did not eliminate socioeconomic disparities among users that were apparent prior to approval, study findings indicate.

17-06-2022 | Oncology | News | Article

CheckMate 9ER update confirms first-line nivolumab plus cabozantinib benefits for advanced RCC

The latest findings from the CheckMate 9ER trial show that the combination of nivolumab plus cabozantinib continues to offer superior survival to that of sunitinib for patients with treatment-naïve advanced renal cell carcinoma after a median follow-up of 32.9 months.

06-06-2022 | Oncology | News | Article

Acetaminophen may blunt ICI response in people with cancer

French researchers have identified an association between detectable plasma levels of acetaminophen and poor outcomes in people receiving immune checkpoint inhibitors for advanced cancer.

04-06-2022 | Oncology | News | Article

Adjuvant everolimus may benefit RCC patients at high risk for recurrence

Adjuvant everolimus may improve recurrence-free survival after nephrectomy in people with treatment-naïve renal cell carcinoma, particularly those with a very high risk for recurrence, suggest final results from the EVEREST trial.

Neurons_illustration (iStock-1224591033)

27-04-2022 | Oncology | News | Article

Neurologic AE risk lower with ICIs vs chemotherapy

The risk for neurologic adverse events is significantly lower with immune checkpoint inhibitors than with other cancer treatments, particularly chemotherapy, suggest results of a systematic review and meta-analysis.

26-04-2022 | Oncology | News | Article

Cabozantinib shows promise for untreated collecting duct RCC

The BONSAI trial has demonstrated encouraging efficacy and manageable toxicity of cabozantinib in treatment-naïve patients with metastatic collecting duct renal cell carcinoma.

22-02-2022 | Oncology | News | Article

​​​​​​​NeoAvAx shows promise of neoadjuvant avelumab–axitinib for localized high-risk RCC

The NeoAvAx trial has demonstrated encouraging response and disease-free survival after neoadjuvant treatment with avelumab plus axitinib in people with locally advanced renal cell carcinoma at high risk for relapse after nephrectomy.

22-02-2022 | Oncology | News | Article

Sustained DFS benefit with adjuvant pembrolizumab in high-risk RCC

Extended follow-up data from the KEYNOTE-564 study show that adjuvant pembrolizumab continues to offer a disease-free survival benefit over placebo in people with renal cell carcinoma at an intermediate-high or high postsurgery recurrence risk.

20-02-2022 | Oncology | News | Article

​​​​​​​Combined nivolumab, axitinib treatment elicits good response in metastatic RCC

Combination treatment with nivolumab plus axitinib has achieved a high response rate in patients with metastatic renal cell carcinoma enrolled in a phase 1/2 trial.


19-01-2022 | Oncology | News | Article

CheckMate 9ER HRQoL data support first-line nivolumab–cabozantinib in advanced RCC

People receiving nivolumab plus cabozantinib for advanced renal cell carcinoma report less decline in health-related quality of life during treatment than those given sunitinib, show data from the phase 3 CheckMate 9ER trial.

18-01-2022 | Oncology | News | Article

Reassurance on radiotherapy use prior to ICI initiation

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

23-12-2021 | Oncology | News | Article

EMA issues positive GU cancer opinions

Read more about the urothelial cancer and renal cell carcinoma decisions here

16-12-2021 | Oncology | News | Article

HLA-A*03 shows potential as a biomarker for ICI response

The risk for disease progression or death increases with HLA-A*03 allele count in people undergoing immune checkpoint inhibitor therapy for cancer, irrespective of tumor type and agent used, research suggests.

02-11-2021 | Oncology | News | Article

Radiotherapy without systemic therapy feasible for oligometastatic RCC

Definitive radiotherapy without systemic therapy may be a feasible strategy for the treatment of oligometastatic renal cell carcinoma, phase 2 study findings indicate.